For individuals living with type 2 diabetes, managing blood sugar is only one piece of a complex health puzzle. Increasingly, research highlights the critical importance of protecting kidney function. A latest study, published in JAMA Internal Medicine, offers compelling evidence that a class of diabetes medications called SGLT2 inhibitors may offer superior kidney protection compared to GLP-1 receptor agonists, a finding that could reshape treatment guidelines. This research, focusing on long-term outcomes, adds to a growing body of evidence suggesting a nuanced approach to medication selection for those with diabetes and at risk of kidney disease.
The study, conducted by researchers in Denmark, analyzed data from over 55,000 patients diagnosed with type 2 diabetes. Participants, all already taking metformin, began either an SGLT2 inhibitor or a GLP-1 receptor agonist between January 2014 and November 2020, with follow-up continuing through October 2024. Researchers utilized a “targeted emulation of a trial” design, a method used to mimic the conditions of a randomized controlled trial using real-world observational data. This approach is particularly valuable when direct comparative trials are lacking, as is the case here. The primary focus was to determine the incidence of acute kidney injury (AKI) and chronic kidney disease (CKD) among the two groups.
SGLT2 Inhibitors Showed a Notable Reduction in Kidney Risks
After five years of observation, the study revealed a statistically significant difference in the risk of chronic kidney disease. Patients initiating treatment with an SGLT2 inhibitor experienced a 6.7% rate of CKD, compared to 8.2% in those starting a GLP-1 receptor agonist. This translated to a 19% relative risk reduction (risk ratio of 0.81) and an absolute risk reduction of 1.5%. The data likewise indicated a reduction in acute kidney injury, with 25.2 events per 100 patients in the SGLT2 inhibitor group versus 28.7 events per 100 patients in the GLP-1 receptor agonist group – a 12% relative risk reduction.
Researchers defined CKD based on a 40% reduction in estimated glomerular filtration rate (eGFR), severe albuminuria, or kidney failure. These are all key indicators of declining kidney function. While secondary outcomes, such as albuminuria and mortality, showed slight reductions in the GLP-1 receptor agonist group, the benefits were less pronounced than those observed with SGLT2 inhibitors. Importantly, the protective effects of SGLT2 inhibitors were most significant among patients without pre-existing kidney disease, suggesting a potential for primary prevention of kidney complications.
Subgroup Analysis Reinforces Findings Across Patient Profiles
The study’s strength lies in its large sample size and comprehensive analysis. Researchers accounted for potential confounding factors by stratifying results based on pre-existing cardiovascular and kidney disease. The consistent findings across these subgroups bolster the reliability of the results. This means the observed benefits of SGLT2 inhibitors weren’t limited to a specific subset of patients but appeared to hold true across a broad range of individuals with type 2 diabetes.
Implications for Clinical Practice and Current Guidelines
The findings challenge current treatment recommendations from organizations like the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). These guidelines currently present SGLT2 inhibitors and GLP-1 receptor agonists as roughly equivalent options for managing type 2 diabetes, particularly in the presence of kidney disease. The Danish study, along with other emerging meta-analyses, suggests a need to re-evaluate these recommendations.
“This study provides strong data suggesting that initiating an SGLT2 inhibitor, even as early as dual therapy and in the absence of nephropathy, is protective,” explains Dr. Søren Skov Jensen, lead author of the study. “This should be a key consideration when choosing between initial antihyperglycemic strategies.” SGLT2 inhibitors perform by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine. This mechanism not only lowers blood sugar but also reduces pressure within the kidneys, offering a protective effect. GLP-1 receptor agonists, primarily work by stimulating insulin release and suppressing glucagon secretion, with a more modest impact on albuminuria.
The implications extend beyond diabetes management. Given the strong link between diabetes and cardiovascular disease and the known benefits of SGLT2 inhibitors in heart failure, these findings further solidify their role as a cornerstone of care for many patients. The National Kidney Foundation offers resources for patients and healthcare professionals seeking more information about diabetes-related kidney disease.
Looking Ahead: Refining Treatment Strategies
While this study provides valuable insights, further research is needed. Direct comparative randomized controlled trials, though challenging to conduct, would provide definitive evidence. In the meantime, clinicians should carefully consider these findings when making treatment decisions for patients with type 2 diabetes, particularly those at risk of kidney complications. The study underscores the importance of personalized medicine, tailoring treatment strategies to individual patient profiles and risk factors.
The next major update to the ADA/EASD guidelines is expected in late 2026. It will be crucial to see whether these new findings are incorporated into the updated recommendations, potentially leading to a shift in clinical practice and improved outcomes for individuals living with type 2 diabetes.
Have thoughts on this new research? Share your comments below, and please share this article with anyone who might find it helpful.
